Discovering and developing novel drugs for cancer treatment

Terpenoid Therapeutics, Inc. is a privately-held biotechnology company focused on anti-cancer therapeutics. We use the platform of terpene chemistry to develop candidate drug molecules. Our team is creating, testing, and developing novel drug candidates using cutting-edge technologies. We seek to generate a robust pipeline of terpene-derived therapeutic agents. Two projects are in advanced preclinical testing with lead compounds identified in both projects.


Terpenoid Bisphosphonates

Terpenoid's bisphosphonate project is based on proprietary terpenoid-modified bisphosphonate inhibitors of geranylgeranyl diphosphate synthase (GGDPS), a novel target for which there are currently no approved drugs. Terpenoid predicts that inhibition of GGDPS will result in efficacy in the treatment of primary tumors and metastases (including, but not limited to, bone metastases).

Terpenoid Schweinfurthins

Terpenoid's schweinfurthin project is focused on discovering and developing a drug with activity against primary tumors and metastases. This project is based on rare schweinfurthin natural products whose unique profile of anti-cancer activity was first reported by the National Cancer Institute in 1998

Terpenoid Therapeutics secures private, NIH financing for drug development

  By Terpenoid | - 12:29 pm | News

University of Iowa News Release Terpenoid Therapeutics Inc., a University of Iowa spinout company based in Coralville, Iowa, has secured nearly $2.5 million in both private investments as well as grants from the National Institutes of Health (NIH) to advance cancer drug candidates toward commercialization. The company raised $1.5 million … Read more